An alternative approach may offer protection against serious pneumococcal infections: a plain language summary of preclinical studies

Plain Language SummaryWhat is this summary about?Current pneumococcal vaccines target pneumococcus type 3, yet this type remains a significant contributor to the global disease burden, highlighting the need for improved protection. This summary explores the potential of an alternative pneumococcal vaccine, developed using MAPS technology (MAPS vaccine), to enhance protection against pneumococcal type 3 disease based on results from laboratory mice.What were the key results and what do they mean?Researchers gave laboratory mice either a MAPS vaccine or PCV13, a widely used pneumococcal conjugate vaccine. This process is called immunization. The researchers compared how well the two vaccines protected mice against disease caused by pneumococcus type 3.In this study, mice given the MAPS vaccine had greater protection than mice given PCV13.MAPS vaccines combine proteins shared by many types of pneumococcus with sugars found on the bacteria’s surface. The results suggest that this combination may help produce an immune response against pneumococcus type 3, which can be difficult to target.

Authors

Institutions

Publication Details

Journal
Human Vaccines & Immunotherapeutics
Published
2026-11-16
DOI
https://doi.org/10.1080/21645515.2026.2754676
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

An alternative approach may offer protection against serious pneumococcal infections: a plain language summary of preclinical studies

David O. Willer, Shite Sebastian, Gilles Besin, Sara E. Roggensack et al.
4 links
Human Vaccines & Immunotherapeutics
Pneumonia and Respiratory Infections
article

An alternative approach may offer protection against serious pneumococcal infections: a plain language summary of preclinical studies

David O. Willer, Shite Sebastian, Gilles Besin, Sara E. Roggensack, Taylor C. Stevenson, Anthony Pratt, Richard Malley, Cathy Srokowski, Aquib Hossain, Pallab Ghosh, Heidi Burke, Fan Zhang, Yingjie Lu
article en

Abstract

Plain Language SummaryWhat is this summary about?Current pneumococcal vaccines target pneumococcus type 3, yet this type remains a significant contributor to the global disease burden, highlighting the need for improved protection. This summary explores the potential of an alternative pneumococcal vaccine, developed using MAPS technology (MAPS vaccine), to enhance protection against pneumococcal type 3 disease based on results from laboratory mice.What were the key results and what do they mean?Researchers gave laboratory mice either a MAPS vaccine or PCV13, a widely used pneumococcal conjugate vaccine. This process is called immunization. The researchers compared how well the two vaccines protected mice against disease caused by pneumococcus type 3.In this study, mice given the MAPS vaccine had greater protection than mice given PCV13.MAPS vaccines combine proteins shared by many types of pneumococcus with sugars found on the bacteria’s surface. The results suggest that this combination may help produce an immune response against pneumococcus type 3, which can be difficult to target.

Human Vaccines & ImmunotherapeuticsVol. 22(1)
Boston Children's Hospital (US), GlaxoSmithKline (Canada) (CA), GlaxoSmithKline (Germany) (DE)
Good health and well-being
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon